Intravenous immunoglobulin and partner specific thrombocyte transfusion immunotherapy in selected cases of recurrent miscarriage

Gyoőzoő Petrányi, Péter Simsa, Ágnes Padányi, Beatrix Kotlán, Judit Jakab, V. Fülöp

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To summarize the immunological diagnostic methods and treatment options for the successful intravenous immunoglobulin (IVIG) and thrombocyte transfusion immunotherapy in recurrent miscarriage (RM) patients. STUDY DESIGN: A total of 191 couples with RM were selected for the study. Gynecological, endocrinological, genetic, infectious, and autoimmune backgrounds were excluded. Immunological tests were performed to identify cases with alloimmune etiology (immunologically related RM [IR/RM]). IVIG, thrombocyte transfusion (partner-specific transfusion [PST]), and a combination of the above (IVIG+PST) were administered to IR/RM patients. RESULTS: In IR/RM patients, partner-specific cytotoxic T lymphocyte precursor frequency (1:8,238) was 8 times higher and NK cell activity was also significantly higher (58.6%) than in normal controls (1:67,517 and 38.1%, respectively). In the sera of IR/RM patients the erythrocyte antibody rosette inhibitory activity was decreased (15.9%) as compared to that of the controls (49.5%). Partner-specific mixed lymphocyte culture (MLC) reactivity showed bidirectional results. While 63% of the patients’ sera expressed enhancing or neutral effects on the basic partner-specific MLC reactions in 37% of the cases, maternal sera blocked the antipaternal MLC reactivity. The overall efficacy of immunotherapy (IVIG, PST, and combina-tion) in selected alloimmune RM cases was 91.5%. CONCLUSION: The efficacy of immunotherapy in RM cases depends on the diagnostic selection of RM patients with alloimmune background. Instead of leukocytes, thrombocytes could be used for immunotherapy with similar efficacy.

Original languageEnglish
Pages (from-to)13-20
Number of pages8
JournalJournal of Reproductive Medicine
Volume63
Issue number1
Publication statusPublished - Feb 1 2018

Fingerprint

Habitual Abortion
Intravenous Immunoglobulins
Immunotherapy
Blood Platelets
Serum
Lymphocytes
Immunologic Tests
Mixed Lymphocyte Culture Test
Cytotoxic T-Lymphocytes
Natural Killer Cells
Leukocytes
Erythrocytes
Mothers
Antibodies

Keywords

  • Abortion
  • Abortion
  • Blocking antibodies
  • Habitual
  • Immune related recurrent miscarriages
  • Immunity
  • Immunologic factors
  • Immunotherapy
  • Intravenous immunoglobulins
  • IVIG
  • Miscarriage
  • Miscarriage
  • Pregnancy complications
  • Recurrent
  • Recurrent

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Cite this

Intravenous immunoglobulin and partner specific thrombocyte transfusion immunotherapy in selected cases of recurrent miscarriage. / Petrányi, Gyoőzoő; Simsa, Péter; Padányi, Ágnes; Kotlán, Beatrix; Jakab, Judit; Fülöp, V.

In: Journal of Reproductive Medicine, Vol. 63, No. 1, 01.02.2018, p. 13-20.

Research output: Contribution to journalArticle

Petrányi, Gyoőzoő ; Simsa, Péter ; Padányi, Ágnes ; Kotlán, Beatrix ; Jakab, Judit ; Fülöp, V. / Intravenous immunoglobulin and partner specific thrombocyte transfusion immunotherapy in selected cases of recurrent miscarriage. In: Journal of Reproductive Medicine. 2018 ; Vol. 63, No. 1. pp. 13-20.
@article{3aa53549988c4848a023077ea208557b,
title = "Intravenous immunoglobulin and partner specific thrombocyte transfusion immunotherapy in selected cases of recurrent miscarriage",
abstract = "OBJECTIVE: To summarize the immunological diagnostic methods and treatment options for the successful intravenous immunoglobulin (IVIG) and thrombocyte transfusion immunotherapy in recurrent miscarriage (RM) patients. STUDY DESIGN: A total of 191 couples with RM were selected for the study. Gynecological, endocrinological, genetic, infectious, and autoimmune backgrounds were excluded. Immunological tests were performed to identify cases with alloimmune etiology (immunologically related RM [IR/RM]). IVIG, thrombocyte transfusion (partner-specific transfusion [PST]), and a combination of the above (IVIG+PST) were administered to IR/RM patients. RESULTS: In IR/RM patients, partner-specific cytotoxic T lymphocyte precursor frequency (1:8,238) was 8 times higher and NK cell activity was also significantly higher (58.6{\%}) than in normal controls (1:67,517 and 38.1{\%}, respectively). In the sera of IR/RM patients the erythrocyte antibody rosette inhibitory activity was decreased (15.9{\%}) as compared to that of the controls (49.5{\%}). Partner-specific mixed lymphocyte culture (MLC) reactivity showed bidirectional results. While 63{\%} of the patients’ sera expressed enhancing or neutral effects on the basic partner-specific MLC reactions in 37{\%} of the cases, maternal sera blocked the antipaternal MLC reactivity. The overall efficacy of immunotherapy (IVIG, PST, and combina-tion) in selected alloimmune RM cases was 91.5{\%}. CONCLUSION: The efficacy of immunotherapy in RM cases depends on the diagnostic selection of RM patients with alloimmune background. Instead of leukocytes, thrombocytes could be used for immunotherapy with similar efficacy.",
keywords = "Abortion, Abortion, Blocking antibodies, Habitual, Immune related recurrent miscarriages, Immunity, Immunologic factors, Immunotherapy, Intravenous immunoglobulins, IVIG, Miscarriage, Miscarriage, Pregnancy complications, Recurrent, Recurrent",
author = "Gyoőzoő Petr{\'a}nyi and P{\'e}ter Simsa and {\'A}gnes Pad{\'a}nyi and Beatrix Kotl{\'a}n and Judit Jakab and V. F{\"u}l{\"o}p",
year = "2018",
month = "2",
day = "1",
language = "English",
volume = "63",
pages = "13--20",
journal = "The Journal of reproductive medicine",
issn = "0024-7758",
publisher = "Donna Kessel",
number = "1",

}

TY - JOUR

T1 - Intravenous immunoglobulin and partner specific thrombocyte transfusion immunotherapy in selected cases of recurrent miscarriage

AU - Petrányi, Gyoőzoő

AU - Simsa, Péter

AU - Padányi, Ágnes

AU - Kotlán, Beatrix

AU - Jakab, Judit

AU - Fülöp, V.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - OBJECTIVE: To summarize the immunological diagnostic methods and treatment options for the successful intravenous immunoglobulin (IVIG) and thrombocyte transfusion immunotherapy in recurrent miscarriage (RM) patients. STUDY DESIGN: A total of 191 couples with RM were selected for the study. Gynecological, endocrinological, genetic, infectious, and autoimmune backgrounds were excluded. Immunological tests were performed to identify cases with alloimmune etiology (immunologically related RM [IR/RM]). IVIG, thrombocyte transfusion (partner-specific transfusion [PST]), and a combination of the above (IVIG+PST) were administered to IR/RM patients. RESULTS: In IR/RM patients, partner-specific cytotoxic T lymphocyte precursor frequency (1:8,238) was 8 times higher and NK cell activity was also significantly higher (58.6%) than in normal controls (1:67,517 and 38.1%, respectively). In the sera of IR/RM patients the erythrocyte antibody rosette inhibitory activity was decreased (15.9%) as compared to that of the controls (49.5%). Partner-specific mixed lymphocyte culture (MLC) reactivity showed bidirectional results. While 63% of the patients’ sera expressed enhancing or neutral effects on the basic partner-specific MLC reactions in 37% of the cases, maternal sera blocked the antipaternal MLC reactivity. The overall efficacy of immunotherapy (IVIG, PST, and combina-tion) in selected alloimmune RM cases was 91.5%. CONCLUSION: The efficacy of immunotherapy in RM cases depends on the diagnostic selection of RM patients with alloimmune background. Instead of leukocytes, thrombocytes could be used for immunotherapy with similar efficacy.

AB - OBJECTIVE: To summarize the immunological diagnostic methods and treatment options for the successful intravenous immunoglobulin (IVIG) and thrombocyte transfusion immunotherapy in recurrent miscarriage (RM) patients. STUDY DESIGN: A total of 191 couples with RM were selected for the study. Gynecological, endocrinological, genetic, infectious, and autoimmune backgrounds were excluded. Immunological tests were performed to identify cases with alloimmune etiology (immunologically related RM [IR/RM]). IVIG, thrombocyte transfusion (partner-specific transfusion [PST]), and a combination of the above (IVIG+PST) were administered to IR/RM patients. RESULTS: In IR/RM patients, partner-specific cytotoxic T lymphocyte precursor frequency (1:8,238) was 8 times higher and NK cell activity was also significantly higher (58.6%) than in normal controls (1:67,517 and 38.1%, respectively). In the sera of IR/RM patients the erythrocyte antibody rosette inhibitory activity was decreased (15.9%) as compared to that of the controls (49.5%). Partner-specific mixed lymphocyte culture (MLC) reactivity showed bidirectional results. While 63% of the patients’ sera expressed enhancing or neutral effects on the basic partner-specific MLC reactions in 37% of the cases, maternal sera blocked the antipaternal MLC reactivity. The overall efficacy of immunotherapy (IVIG, PST, and combina-tion) in selected alloimmune RM cases was 91.5%. CONCLUSION: The efficacy of immunotherapy in RM cases depends on the diagnostic selection of RM patients with alloimmune background. Instead of leukocytes, thrombocytes could be used for immunotherapy with similar efficacy.

KW - Abortion

KW - Abortion

KW - Blocking antibodies

KW - Habitual

KW - Immune related recurrent miscarriages

KW - Immunity

KW - Immunologic factors

KW - Immunotherapy

KW - Intravenous immunoglobulins

KW - IVIG

KW - Miscarriage

KW - Miscarriage

KW - Pregnancy complications

KW - Recurrent

KW - Recurrent

UR - http://www.scopus.com/inward/record.url?scp=85041016275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041016275&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85041016275

VL - 63

SP - 13

EP - 20

JO - The Journal of reproductive medicine

JF - The Journal of reproductive medicine

SN - 0024-7758

IS - 1

ER -